Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia

    loading  Checking for direct PDF access through Ovid

Abstract

Immunovirological consequences of a switch to a maraviroc/raltegravir dual therapy were analyzed in 16 HIV-infected patients with persistent viral load below 50 copies/ml. At 26-week postswitch, the CD4+/CD8+ ratio decreased and the CD8+ T-cell activation increased. A decrease in classical monocytes was associated with a shift toward a proinflammatory monocyte profile and negatively correlated with ultrasensitive viral load. Thus, this therapeutic switch induced a proinflammatory profile probably driven by a slight loss of virus control.

Related Topics

    loading  Loading Related Articles